DRAK2 Polyclonal Antibody, Invitrogen™

Description

• This antibody is predicted to react with canine based on sequence homology
• This antibody is tested in Peptide ELISA: antibody detection limit dilution 32,000
• STK17B (also known as DRAK2) is a member of the serine/threonine kinase family and is related to death-associated protein kinase that triggers apoptosis
• STK17B is selectively important for T-cell survival and inhibition of STK17B has therapeutic potential for autoimmune disease
• T-cell survival depends on a balance of T-cell receptor and co-stimulatory signals and deficiency of STK17B can affect autoimmune disease susceptibility without generalized suppression of the immune system
• Protein kinases play important roles in the signal transduction in response to a variety of external stimuli
• Recently, several protein kinases have been identified that may also be involved in apoptotic process
• Overexpression of a serine/threonine kinase, ZIP kinase can cause the morphological changes typical of apoptosis in NIH 3T3 cells
• Sanjo et al, have identified two new protein kinases DRAK1 and DRAK2 (Death Receptor Associated Kinase 1 and 2)
• Both DRAKs and ZIP kinase share significant homology at the amino acid level
• The kinase domains of both DRAKs, ZIP kinase are homologous to DAP (Death-associated protein) kinase, which is involved in the apoptotic signaling induced by interferon-g
• Overexpression of DRAKs in NIH 3T3 cells lead to apoptosis
• These transfection experiments suggest that C-terminal domain of DRAKs are important for induction of apoptosis.